Evidence map›Paper›PMID 41984093›Full record

ArticleArchives of toxicology2026

Mapping 3Rs and NAM research and innovation projects funded through European framework programmes since 2007.

Julia Matyjasiak, Alexandra-Costina Avîrvarei, Marie Corradi, Amy Maerten, Christian Desaintes, Julen Sanz-Serrano, Mathieu Vinken

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julia Matyjasiak *Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.ORCID 0009-0004-6043-9645
Alexandra-Costina AvîrvareiDepartment of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.ORCID 0009-0001-2069-4420
Marie CorradiInnovative Testing in Life Sciences and Chemistry, Utrecht University of Applied Sciences, Utrecht, The Netherlands.ORCID 0000-0001-8185-5913
Amy MaertenDepartment of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.ORCID 0000-0002-6208-636X
Christian DesaintesEuropean Commission, Brussels, Belgium.ORCID 0000-0003-4165-3297
Julen Sanz-Serrano *Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium.ORCID 0000-0002-0503-2752
Mathieu Vinken *Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090, Brussels, Belgium. mathieu.vinken@vub.be.ORCID 0000-0001-5115-8893

Funding

Research Foundation Flanders 1S81326N
6 · The paper itself

Abstract

The development of new approach methodologies (NAMs) is increasingly enabling the replacement and reduction of animal use in research, complementing the ethical framework provided by the 3Rs (replacement, refinement, and reduction) of animal research. The European Commission has supported these approaches by embedding 3R requirements in policy frameworks and providing dedicated funding for 3Rs/NAMs-related research. However, a systematic and comprehensive overview on European Union (EU) research funding of these projects is lacking. In this study, projects funded under Framework Programme 7 (2007-2013), Horizon 2020 (2014-2020) and Horizon Europe (2021-2027, extracted until March 2025) were analysed using the EU Community Research and Development Information Service database (CORDIS). A 2-tiered artificial intelligence-based data retrieval approach was applied, combining supervised text classification and semantic search followed by expert review, yielding a total of 539 relevant projects. Approximately 40% of these projects were toxicology-related, while the remainder pertained to areas such as disease research or technology scaling. Across the portfolio, oncology and neuroscience emerged as major application areas, with a strong representation of in vitro methodologies, including 3D cell culture methods and engineered models such as organs-on-chip, alongside in silico technologies. In terms of country participation and collaboration, Western European countries occupied central positions in obtaining funding and leading research efforts in this field. Overall, these findings demonstrate that EU framework programmes have provided substantial and sustained support for 3Rs/NAMs research and innovation, while also highlighting thematic and geographic imbalances that can inform future research and policy initiatives.

Indexed as

Animal Testing AlternativesAnimal Use AlternativesAnimalsDatabases, FactualEuropeEuropean UnionHumans3RsAIAnimal testing alternativesNAMs

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.